Concurrent Androgen Deprivation Therapy for Prostate Cancer Improves Survival for Synchronous or Metachronous Non-Small Cell Lung Cancer: A SEER–Medicare Database Analysis
Introduction: The crosstalk between receptor kinase signaling, such as EGFR and androgen receptor signaling, suggests a potential interaction between androgen deprivation therapy (ADT) and lung cancer outcome. Methods: We employed the SEER–Medicare data of lung cancer patients diagnosed between 1988...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-06-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/13/3206 |
| _version_ | 1797480627011846144 |
|---|---|
| author | Bassel Nazha Chao Zhang Zhengjia Chen Camille Ragin Taofeek K. Owonikoko |
| author_facet | Bassel Nazha Chao Zhang Zhengjia Chen Camille Ragin Taofeek K. Owonikoko |
| author_sort | Bassel Nazha |
| collection | DOAJ |
| description | Introduction: The crosstalk between receptor kinase signaling, such as EGFR and androgen receptor signaling, suggests a potential interaction between androgen deprivation therapy (ADT) and lung cancer outcome. Methods: We employed the SEER–Medicare data of lung cancer patients diagnosed between 1988 and 2005 to test for an association between ADT for prostate cancer and lung cancer outcome. We employed the Kaplan–Meier method and Cox proportional hazard with log-rank test model to assess any significant impact of ADT on survival. Results: We included data from 367,750 lung cancer patients; 17.4%, 2.9%, 33.6% and 46.1% with stages I, II, III and IV, respectively; 84.5% were >65 years; 57.2% males; 84.2% Caucasians and 9.3% Blacks. There were 11,061 patients (3%) with an initial prostate cancer diagnosis followed by lung cancer (P-L group); 3017 (0.8%) with an initial diagnosis of lung cancer and subsequent prostate cancer diagnosis (L-P group); the remainder had only lung cancer (L group). Stage I lung cancer was most common in the L-P group compared to the L and P-L groups—54% vs. 17.13% vs. 17.92%, <i>p</i> < 0.0001 for L-P, L and P-L, respectively. The median OS for lung cancer diagnosis was 93 months versus 10 and 9 months, respectively, for the L-P, L and P-L subgroups. ADT was associated with improved survival on multivariate analysis, especially in Caucasian patients (HR of death: 0.86; 95% CI: 0.76–0.97; <i>p</i> = 0.012). Conclusion: ADT was associated with improved outcome for NSCLC, in line with the hypothesis of a role for the androgen receptor in lung cancer. Our findings support a systematic evaluation of the potential benefit of ADT as a therapy for lung cancer. |
| first_indexed | 2024-03-09T22:02:45Z |
| format | Article |
| id | doaj.art-a23b76e658f1441d8b8af6f7315b16af |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T22:02:45Z |
| publishDate | 2022-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-a23b76e658f1441d8b8af6f7315b16af2023-11-23T19:46:11ZengMDPI AGCancers2072-66942022-06-011413320610.3390/cancers14133206Concurrent Androgen Deprivation Therapy for Prostate Cancer Improves Survival for Synchronous or Metachronous Non-Small Cell Lung Cancer: A SEER–Medicare Database AnalysisBassel Nazha0Chao Zhang1Zhengjia Chen2Camille Ragin3Taofeek K. Owonikoko4Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA 30322, USADepartment of Biostatistics, Rollins School of Public Health, Winship Cancer Institute of Emory University, Atlanta, GA 30322, USADivision of Epidemiology and Biostatistics, School of Public Health, University of Illinois at Chicago, Chicago, IL 60607, USADepartment of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USADepartment of Medicine, Division of Hematology/Oncology, University of Pittsburgh, UPMC Hillman Cancer Center, 5150 Centre Avenue, Pittsburgh, PA 15260, USAIntroduction: The crosstalk between receptor kinase signaling, such as EGFR and androgen receptor signaling, suggests a potential interaction between androgen deprivation therapy (ADT) and lung cancer outcome. Methods: We employed the SEER–Medicare data of lung cancer patients diagnosed between 1988 and 2005 to test for an association between ADT for prostate cancer and lung cancer outcome. We employed the Kaplan–Meier method and Cox proportional hazard with log-rank test model to assess any significant impact of ADT on survival. Results: We included data from 367,750 lung cancer patients; 17.4%, 2.9%, 33.6% and 46.1% with stages I, II, III and IV, respectively; 84.5% were >65 years; 57.2% males; 84.2% Caucasians and 9.3% Blacks. There were 11,061 patients (3%) with an initial prostate cancer diagnosis followed by lung cancer (P-L group); 3017 (0.8%) with an initial diagnosis of lung cancer and subsequent prostate cancer diagnosis (L-P group); the remainder had only lung cancer (L group). Stage I lung cancer was most common in the L-P group compared to the L and P-L groups—54% vs. 17.13% vs. 17.92%, <i>p</i> < 0.0001 for L-P, L and P-L, respectively. The median OS for lung cancer diagnosis was 93 months versus 10 and 9 months, respectively, for the L-P, L and P-L subgroups. ADT was associated with improved survival on multivariate analysis, especially in Caucasian patients (HR of death: 0.86; 95% CI: 0.76–0.97; <i>p</i> = 0.012). Conclusion: ADT was associated with improved outcome for NSCLC, in line with the hypothesis of a role for the androgen receptor in lung cancer. Our findings support a systematic evaluation of the potential benefit of ADT as a therapy for lung cancer.https://www.mdpi.com/2072-6694/14/13/3206prostate cancerlung cancerhormonal therapyandrogen deprivation therapySEER |
| spellingShingle | Bassel Nazha Chao Zhang Zhengjia Chen Camille Ragin Taofeek K. Owonikoko Concurrent Androgen Deprivation Therapy for Prostate Cancer Improves Survival for Synchronous or Metachronous Non-Small Cell Lung Cancer: A SEER–Medicare Database Analysis Cancers prostate cancer lung cancer hormonal therapy androgen deprivation therapy SEER |
| title | Concurrent Androgen Deprivation Therapy for Prostate Cancer Improves Survival for Synchronous or Metachronous Non-Small Cell Lung Cancer: A SEER–Medicare Database Analysis |
| title_full | Concurrent Androgen Deprivation Therapy for Prostate Cancer Improves Survival for Synchronous or Metachronous Non-Small Cell Lung Cancer: A SEER–Medicare Database Analysis |
| title_fullStr | Concurrent Androgen Deprivation Therapy for Prostate Cancer Improves Survival for Synchronous or Metachronous Non-Small Cell Lung Cancer: A SEER–Medicare Database Analysis |
| title_full_unstemmed | Concurrent Androgen Deprivation Therapy for Prostate Cancer Improves Survival for Synchronous or Metachronous Non-Small Cell Lung Cancer: A SEER–Medicare Database Analysis |
| title_short | Concurrent Androgen Deprivation Therapy for Prostate Cancer Improves Survival for Synchronous or Metachronous Non-Small Cell Lung Cancer: A SEER–Medicare Database Analysis |
| title_sort | concurrent androgen deprivation therapy for prostate cancer improves survival for synchronous or metachronous non small cell lung cancer a seer medicare database analysis |
| topic | prostate cancer lung cancer hormonal therapy androgen deprivation therapy SEER |
| url | https://www.mdpi.com/2072-6694/14/13/3206 |
| work_keys_str_mv | AT basselnazha concurrentandrogendeprivationtherapyforprostatecancerimprovessurvivalforsynchronousormetachronousnonsmallcelllungcanceraseermedicaredatabaseanalysis AT chaozhang concurrentandrogendeprivationtherapyforprostatecancerimprovessurvivalforsynchronousormetachronousnonsmallcelllungcanceraseermedicaredatabaseanalysis AT zhengjiachen concurrentandrogendeprivationtherapyforprostatecancerimprovessurvivalforsynchronousormetachronousnonsmallcelllungcanceraseermedicaredatabaseanalysis AT camilleragin concurrentandrogendeprivationtherapyforprostatecancerimprovessurvivalforsynchronousormetachronousnonsmallcelllungcanceraseermedicaredatabaseanalysis AT taofeekkowonikoko concurrentandrogendeprivationtherapyforprostatecancerimprovessurvivalforsynchronousormetachronousnonsmallcelllungcanceraseermedicaredatabaseanalysis |